EUVIMEDTutustu EUVIMEDiin
ÜbersichtsarbeitOpen access · CC BY 4.0

From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine

Corneliu Toader, Matei Serban, Octavian Munteanu, Razvan-Adrian Covache-Busuioc, Mihaly Enyedi, Alexandru Vlad Ciurea, Calin Petru Tataru

International Journal of Molecular Sciences · 2025-04-30 · 26 (9) · 4271

DOI: 10.3390/ijms26094271 ↗

At a glance

Übersichtsarbeit in International Journal of Molecular Sciences, published online on 2025-04-30. Written by Corneliu Toader and 6 co-authors. Institution: Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. Major MEDLINE topics: Brain-Derived Neurotrophic Factor, Neuronal Plasticity, Neurodegenerative Diseases. Cited 170 times so far (Crossref); 330 references. The full text is freely available (open access, CC BY 4.0). Funded by: University of Medicine and Pharmacy Carol Davila.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

The brain-derived neurotrophic factor (BDNF) has become one of the cornerstones of neuropathology, influencing synaptic plasticity, cognitive resilience, and neuronal survival. Apart from its molecular biology, BDNF is a powerful target for transformative benefit in precision medicine, leading to innovative therapeutic approaches for neurodegenerative and psychiatric diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Nevertheless, clinical applicability is obstructed by hurdles in delivery, patient-specific diversity, and pleiotropic signaling. Here, we summarize findings in BDNF research, including its regulatory pathways and diagnostic/prognostic biomarkers and integrative therapeutic approaches. We describe innovative delivery systems, such as lipid nanoparticle-based mRNA therapies and CRISPR-dCas9-based epigenetic editing that bypass obstacles such as BBB (blood–brain barrier) and enzymatic degradation. The recent implementation of multiplex panels combining BDNF biodynamic indicators with tau and amyloid-β signaling markers showcases novel levels of specificity for both early detection and potential therapeutic monitoring. Humanized preclinical models like iPSC-derived neurons and organoids point to the key role of BDNF in neurodeveloping and neurodegenerative processes, paralleling advances in bridging preclinical observation and clinical environments. Moreover, novel therapeutic tools delivering TrkB activators or the implementation of AI-based dynamic care platforms enable tailored and scalable treatments. This review also aims to extend a framework used in the understanding of BDNF’s relevance to traditional neurodegenerative models by situating more recent work detailing BDNF’s actions in ischemic tissues and the gut–brain axis in the context of systemic health. Finally, we outline a roadmap for the incorporation of BDNF-centered therapies into worldwide healthcare, highlighting ethical issues, equity, and interdisciplinary decomposition. The therapeutic potential of BDNF heralds a new era in neuroscience and medicine, revolutionizing brain health and paving the way for the advancement of precision medicine.

Subjects

MeSH terms (MEDLINE)

Brain-Derived Neurotrophic FactorNeuronal PlasticityNeurodegenerative DiseasesHumansAnimalsBiomarkers

Author keywords

Alzheimer’s diseaseBDNFCRISPRTrkB agonistsneurotrophic signalingpersonalized therapiesprecision medicinesynaptic plasticity

Substances

Brain-Derived Neurotrophic FactorBDNF protein, humanBiomarkers

Authors and institutions

  • Department of Neurosurgery, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Vascular Neurosurgery, National Institute of Neurology and Neurovascular Diseases, 077160 Bucharest, Romania.
  • Puls Med Association, 051885 Bucharest, Romania.
  • Department of Anatomy, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Neurosurgery Department, Sanador Clinical Hospital, 010991 Bucharest, Romania.
  • Medical Section, Romanian Academy, 010071 Bucharest, Romania.

Funding

  • University of Medicine and Pharmacy Carol Davila

Cite

APA

Toader, C., Serban, M., Munteanu, O., Covache-Busuioc, R. A., Enyedi, M., Ciurea, A. V., & Tataru, C. P. (2025). From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine. International Journal of Molecular Sciences, 26(9), 4271. https://doi.org/10.3390/ijms26094271

Vancouver

Toader C, Serban M, Munteanu O, Covache-Busuioc RA, Enyedi M, Ciurea AV, et al. From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine. International Journal of Molecular Sciences. 2025;26(9):4271. doi:10.3390/ijms26094271

BibTeX
@article{Toader2025,
  author = {Toader, Corneliu and Serban, Matei and Munteanu, Octavian and Covache-Busuioc, Razvan-Adrian and Enyedi, Mihaly and Ciurea, Alexandru Vlad and Tataru, Calin Petru},
  title = {From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {9},
  pages = {4271},
  doi = {10.3390/ijms26094271}
}
Start for free →